Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SURVIVAL AND FEV1 DECLINE IN INDIVIDUALS WITH SEVERE DEFICIENCY OF ALPHA(1)-ANTITRYPSIN
Autore:
VREIM CE; WU M; CRYSTAL RG; BUIST AS; BURROWS B; COHEN AB; FALLAT RJ; GADEK JE; ROUSELL RH; SCHWARTZ RS; TURINO GM; SCHLUCHTER MD; STOLLER JK; WIEDEMANN HP; WILLIAMS GW; BARRETT DM; BECK GJ; MCCARTHY K; MIDCALF V; MOORE B; SARTORI P; SHERER SG; ZHANG R; PETTY TL; TOMASHEFSKI JF; BRANTLY ML; HILDESHEIM J; RUNDQUIST B; SANDHAUS RA; BELL CW; BEREND J; RAVIKRISHNAN KP; BEGLE R; ERB D; SEIDMAN J; SHERMAN S; CAMERON B; WEINBERGER S; ROSENBERG M; JOHNSTON R; ARROLIGA AC; MEEKER DP; MEHTA A; LASKOWSKI D; RYAN WJ; LOFTIN JP; JOHNSON K; KOTCH A; CLARK T; EPSTEIN PE; DELBUONO P; SANDBLOM RE; HERT RC; DEMAINE JB; COLLAR L; EICHENHORN MS; MCMAHAN JP; BREITE WM; WEBBJOHNSON D; CORBETT J; MCMANUS D; KROWKA MJ; ZEIGER T; PRAKASH UBS; STAATS B; NESLER D; STRANGE C; BAUMANN M; JUDSON M; OSER R; SOSKEL NT; SMITH V; KILLIAN DN; DEMICCO W; GOLDEN L; HITCHCOCK R; MOSS J; CHU SC; MCELVANEY NG; BARNES P; ONEIL K; HOLDEN D; METH BM; ASHBURN RW; FORRESTER J; SARLIN RF; SEN RP; WALSH TE; JONES S; WEWERS M; DRAKE J; BARKER AF; OVESON L; SHEEHAN WC; AISENBERG RM; MUCCIARDI N; DEMERS P; TURINO GM; EDEN E; DODGE RR; BURROWS B; KLINK M; CLINE M; CROSS CE; CHAN A; BOOTH A; TIERNEY DF; SHAPIRO B; ELLSTROM K; CLAUSEN JL; BORDERS J; WILSON J; BUCHMAYER J; BITTERMAN P; HARMON K; HERTZ M; EDIN C; RENNARD SI; ROBBINS RA; FOGELMAN R; DONOHUE JF; TURPIN S; HOBNEKER K; WINDERS J; HYDE RW; SPOHN B; STOCKS JM; WALDROP D; CAMPBELL EJ; KANNER RE; POPE C; GROSS N; KING F; WATERS I; HOROWITZ M; NELSON P; PIERCE JA; SILVERMAN E; WILSON P; SNIDER GL; DETRE K; REYNOLDS HY; TOCKMAN MS; WITTES J;
Indirizzi:
CLEVELAND CLIN FDN,DEPT BIOSTAT,DESK P-88,9500 EUCLID AVE CLEVELAND OH 44195 CORNELL UNIV,NEW YORK HOSP ITHACA NY 14853 CLEVELAND CLIN FDN,DEPT BIOSTAT CLEVELAND OH 44195 OREGON HLTH SCI UNIV PORTLAND OR 97201 UNIV NEBRASKA,MED CTR OMAHA NE 00000 UNIV TEXAS,CTR HLTH TYLER TX 75710
Titolo Testata:
American journal of respiratory and critical care medicine
fascicolo: 1, volume: 158, anno: 1998,
pagine: 49 - 59
SICI:
1073-449X(1998)158:1<49:SAFDII>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
ALPHA-1-ANTITRYPSIN DEFICIENCY; REPLACEMENT THERAPY; ALVEOLAR STRUCTURES; LUNG-FUNCTION; PIZ; EMPHYSEMA; HISTORY; DISEASE; SMOKING; MODELS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
37
Recensione:
Indirizzi per estratti:
Citazione:
C.E. Vreim et al., "SURVIVAL AND FEV1 DECLINE IN INDIVIDUALS WITH SEVERE DEFICIENCY OF ALPHA(1)-ANTITRYPSIN", American journal of respiratory and critical care medicine, 158(1), 1998, pp. 49-59

Abstract

Subjects greater than or equal to 18 yr of age with serum alpha(1)-antitrypsin (alpha(1)-AT) levels less than or equal to 11 mu M or a ZZ genotype were followed for 3.5 to 7 yr with spirometry measurements every 6 to 12 mo as part of a National Heart, Lung, and Blood Institute Registry of Patients with Severe Deficiency of Alpha-1-Antitrypsin. Among all 1,129 enrollees, 5-yr mortality was 19% (95% CI: 16 to 21%). Inmultivariate analyses of 1,048 subjects who had been contacted greater than or equal to 6 mo after enrolling, age and baseline FEV1% predicted were significant predictors of mortality. Results also showed thatthose subjects receiving augmentation therapy had decreased mortality(risk ratio [RR] = 0.64, 95% CI: 0.43 to 0.94, p = 0.02) as compared with those not receiving therapy. Among 927 subjects with two or more FEV1 measurements greater than or equal to 1 yr apart, the mean FEV1 decline was 54 ml/yr, with more rapid decline in males, those aged 30 to 44 yr, current smokers, those with FEV1 35 to 79% predicted, and those who ever had a bronchodilator response. Among all subjects, FEV1 decline was not different between augmentation-therapy groups (p = 0.40). However, among subjects with a mean FEV1 35 to 49% predicted, FEV1 decline was significantly slower for subjects receiving than for those not receiving augmentation therapy (mean difference = 27 ml/yr, 95% CI: 3 to 51 ml/yr; p = 0.03). Because this was not a randomized trial, we cannot exclude the possibility that these differences may have been due to other factors for which we could not control.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 12:26:17